These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16369821)

  • 1. Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
    Poujol S; Bressolle F; Duffour J; Abderrahim AG; Astre C; Ychou M; Pinguet F
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):292-305. PubMed ID: 16369821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
    Poujol S; Pinguet F; Ychou M; Abderrahim AG; Duffour J; Bressolle FM
    Oncol Rep; 2007 Dec; 18(6):1613-321. PubMed ID: 17982652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
    Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Matsunaga M; Araki K; Tanaka R; Ichikawa W; Miya T; Narabayashi M; Akiyama Y; Kawara K; Ando Y; Sasaki Y
    Biol Pharm Bull; 2008 Nov; 31(11):2137-42. PubMed ID: 18981587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
    Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
    Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
    Wasserman E; Cuvier C; Lokiec F; Goldwasser F; Kalla S; Méry-Mignard D; Ouldkaci M; Besmaine A; Dupont-André G; Mahjoubi M; Marty M; Misset JL; Cvitkovic E
    J Clin Oncol; 1999 Jun; 17(6):1751-9. PubMed ID: 10561212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
    Deyme L; Barbolosi D; Mbatchi LC; Tubiana-Mathieu N; Ychou M; Evrard A; Gattacceca F
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):247-258. PubMed ID: 33912999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
    de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
    J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
    Horita Y; Yamada Y; Hirashima Y; Kato K; Nakajima T; Hamaguchi T; Shimada Y
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):467-71. PubMed ID: 19554330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
    Masi G; Falcone A; Di Paolo A; Allegrini G; Danesi R; Barbara C; Cupini S; Del Tacca M
    Clin Cancer Res; 2004 Mar; 10(5):1657-63. PubMed ID: 15014016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
    Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
    Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
    Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
    Canal P; Gay C; Dezeuze A; Douillard JY; Bugat R; Brunet R; Adenis A; Herait P; Lokiec F; Mathieu-Boue A
    J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.
    Gkioulbasanis I; Souglakos J; Vardakis N; Kotsakis A; Saridaki Z; Kentepozidis N; Polyzos A; Giassas S; Ignatiadis M; Bozionelou V; Christophylakis C; Georgoulias V
    J BUON; 2007; 12(2):197-202. PubMed ID: 17600872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
    Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P
    J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
    Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
    Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.